Ofatumumab - a new high-efficacy treatment for relapsing forms of multiple sclerosis

被引：0

作者：

Valis, M. ^{[1
]}

Haluskova, S. ^{[1
]}

机构：

[1] Neurol Klinika LF UK FN Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic

来源：

CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE | 2021年 / 84卷 / 05期

关键词：

multiple sclerosis; treatment; antibodies monoclonal; ofatumumab; DISEASE-ACTIVITY; NO EVIDENCE; B-CELLS; OCRELIZUMAB; THERAPIES; ANTIBODY;

D O I：

10.48095/cccsnn2021436

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

There has been tremendous progress in the treatment of MS over recent years. The concept of early treatment to achieve better outcomes in MS has clearly emerged, fully supported by long-term data. The effi cacy of anti-CD20 monoclonal antibodies in the treatment of MS has been confi rmed in clinical trials. Ofatumumab is a fully-humanized anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing-remitting MS. Ofatumumab showed high effi cacy and a favorable safety profile in phase III clinical trials, offering the first B-cell therapy that can be subcutaneously self-administered at home.

引用

页码：436 / 440

页数：5

共 50 条

[21] Ofatumumab in the treatment of multiple sclerosis - A summary of preclinical and clinical data
Klehmet, Juliane
Bopp, Tobias
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2024,
[22] Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis
Samjoo, Imtiaz A.
Klotz, Luisa
Giovannoni, Gavin
Drudge, Christopher
Haltner, Anja
Worthington, Evelyn
Zhao, Melody
Brennan, Roisin
Haring, Dieter A.
Cameron, Chris
Adlard, Nicholas
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 66
[23] Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
Onder, Halil
TURKISH JOURNAL OF NEUROLOGY, 2019, 25 (02) : 105 - 106
[24] Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing-remitting multiple sclerosis
Mariottini, Alice
Nozzoli, Chiara
Carli, Ilaria
Landi, Filippo
Gigli, Valentina
Repice, Anna Maria
Ipponi, Alessandra
Cecchi, Michele
Boncompagni, Riccardo
Saccardi, Riccardo
Massacesi, Luca
NEUROLOGICAL SCIENCES, 2024, 45 (07) : 3379 - 3387
[25] Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data
Ruggieri, Serena
Quartuccio, Maria Esmeralda
Prosperini, Luca
DEGENERATIVE NEUROLOGICAL AND NEUROMUSCULAR DISEASE, 2022, 12 : 61 - 73
[26] New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis
Fox, Edward J.
Rhoades, Robert W.
CURRENT OPINION IN NEUROLOGY, 2012, 25 : S11 - S19
[27] Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study
El Mahdaoui, Sahla
Christensen, Jeppe Romme
Magyari, Melinda
Wandall-Holm, Malthe Faurschou
Sellebjerg, Finn
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 68
[28] Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy
Awada, Zeinab
Hameed, Natasha
Harel, Asaff
DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 5985 - 5996
[29] Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis
Schweitzer, Finja
Laurent, Sarah
Fink, Gereon R.
Barnett, Michael H.
Reddel, Stephen
Hartung, Hans-Peter
Warnke, Clemens
CURRENT OPINION IN NEUROLOGY, 2019, 32 (03) : 305 - 312
[30] Employing novel indirect treatment comparison methodologies to differentiate the efficacy of ofatumumab versus orally administered therapies for relapsing multiple sclerosis
Butzkueven, Helmut
Haltner, Anja
Drudge, Chris
Samjoo, Imtiaz
Barnett, Michael
Broadley, Simon
Mccombe, Pamela
Van der Walt, Anneke
Stoneman, Dee
Merschhemke, Martin
Adlard, Nicholas
Nelson, Morag
Riley, Nicholas
Walker, Rob
MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (04) : 50 - 51

← 1 2 3 4 5 →